How recovery is measured: IKDC and MOCART scores

Two different measurement tools appear throughout the ChondroFiller published literature, and understanding what each one captures makes the outcome figures far easier to interpret.

The IKDC subjective score is filled in by the patient. It runs from 0 to 100 and asks about pain, stiffness, swelling, and how much the joint limits everyday and sporting activity. Think of it as the equivalent of a physiotherapist asking, "How much can you actually do?" — a higher number means fewer restrictions.

The MOCART score is read by a radiologist from an MRI scan. It also runs from 0 to 100 and assesses how completely the treated defect has filled in and how well the new tissue integrates with the surrounding cartilage. Where the IKDC captures lived experience, MOCART captures structural appearance — the equivalent of a radiologist asking, "How does the repair tissue look on the scan?"

Critically, the two scores do not move in lockstep. Independent systematic-review evidence confirms that a high result on one does not reliably predict a high result on the other. In practice, patients often report functional improvement well before MRI scans show full structural maturation — and MRI appearance may continue to improve after functional gains have already levelled off.

One further term appears throughout the evidence: the MCID, or minimal clinically important difference. For the IKDC, this threshold sits at 16.7 points. Any gain smaller than that is statistically detectable in a dataset but not meaningfully perceptible to a patient going about daily life. The MCID is the benchmark used to judge whether a reported improvement actually matters to the person who received treatment.

Functional recovery: what IKDC scores show at 12 months

Moving from a score of roughly 48 to approximately 80 within a year is the headline functional finding across independently published ChondroFiller knee cohorts — a shift that, in practical terms, means going from significant activity limitation to near-normal recreational participation.

The pre-treatment figure of around 48 sits in a range where everyday activities such as sustained walking, stair-climbing, and low-impact exercise typically provoke symptoms. A score of approximately 80 places most recreational sport and physical activity within reach. The gap between those two figures — roughly 30 to 32 points — clears the 16.7-point MCID threshold by a considerable margin, confirming that the improvement registers as genuinely perceptible in daily life rather than as a statistical artefact visible only in spreadsheets.

Two independent study designs report this same magnitude of gain. A 2016 prospective multi-centre pilot recorded statistically significant IKDC improvements at three, six, and twelve months (p<0.05) in the collagen scaffold-treated group. An independent 2024 knee cohort of 17 patients with a mean age of 31 replicated the finding across the same three time points, again reaching significance at each interval.

The 2024 cohort adds a further observation: scores at six and twelve months showed no statistically significant difference (p>0.05). That finding offers a practical anchor — the bulk of functional recovery consolidates within the first year of treatment. Rather than an open-ended waiting period, patients can expect the twelve-month assessment to give a reliable indication of where their functional capacity will settle.

Structural repair: what MRI findings reveal

Published MRI follow-up data indicate that one-year MOCART scores for ChondroFiller-treated knees cluster in the 70–87 out of 100 range, with some cohort means cited between 81.6 and 84.3. Scores at that level indicate substantial defect fill with sound peripheral integration — clinically meaningful progress, though not the same as a complete return to native hyaline cartilage.

A particularly important pattern emerges when MOCART readings are compared across follow-up intervals: MRI structural maturation frequently continues to improve beyond 12 months even after functional IKDC gains have already plateaued. In practical terms, this means a 12-month scan provides a useful interim picture but is likely a conservative estimate of eventual structural quality. Patients who feel close to their functional best by month 12 may see further MRI improvement in the months that follow.

Evidence from laboratory models helps explain why early structural readings remain partial. A 2025 ex vivo study using human osteochondral explants recorded a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, confirming that host progenitor cells actively migrate into the collagen scaffold — the process takes time to unfold. A 2024 biomechanical in-vitro study adds a cautionary note from a different angle: the immature gel did not reduce friction-related damage to opposing cartilage compared with untreated defects, owing to its early mechanical instability. The authors concluded that full weight-bearing should be delayed until structural stability is established — the clinical rationale behind protected weight-bearing protocols used after placement.

The relevance of early mechanical vulnerability extends across joint types, not only the knee. A 2025 cohort study of 25 patients treated for intra-articular wrist fractures found significantly better cartilage quality at follow-up arthroscopy compared with controls — Outerbridge scores of 1.5 versus 3 (p=0.006) and ICRS scores of 1 versus 3 (p=0.002) — broadening the structural evidence base to small joints where the same scaffold behaviour applies.

How long the results last

Durability data beyond the first year are encouraging, and how long results hold depends substantially on who receives treatment in the first place.

The strongest single published anchor comes from a 2021 prospective hip cohort following 26 patients for up to five years. Of the 21 evaluable at long-term follow-up, 17 — approximately 81% — maintained good or excellent results at three, four, and five years. That consistency across successive annual assessments, rather than a single late snapshot, lends the finding particular weight.

Post-market registry data from knee populations add a complementary picture: functional gains recorded at twelve months were not only sustained at three-year follow-up but showed a slight further increase — a trajectory consistent with continuing tissue maturation beyond the first year. Taken across knee, hip, and small-joint published series, evidence suggests that roughly 70–85% of treated patients achieve meaningful symptom relief at three to five years.

The phrase "appropriately selected patients" carries real weight in that figure. Results in cohorts restricted to focal, well-demarcated defects in joints free of generalised disease look markedly better than those where selection criteria are broader. What constitutes appropriate selection is examined more closely in the following section.

Over 19,000 cases have now been treated globally, providing a growing real-world dataset that adds breadth to the published cohort results — though the boundaries of that evidence are worth understanding in their own right.

Which patients see the best outcomes

The evidence base targets a specific population — patients with a contained, well-demarcated area of cartilage damage rather than widespread joint deterioration. In published cohorts, this typically means a focal defect smaller than roughly 2–3 cm² in a joint where the surrounding cartilage and adjacent bone remain broadly intact.

The most important suitability filter is the distinction between focal damage and generalised arthritis. Imaging assessments grade arthritis on a severity scale; at the advanced end of that scale — where cartilage loss is extensive across the joint surface and structural bone changes are already established — published cohorts consistently record poor outcomes with ChondroFiller. The headline figures discussed in earlier sections arise almost exclusively from cohorts that excluded patients at that stage of disease. This is not a limitation of the data; it is the reason the data look the way they do.

Age and activity profile add further context. Simeonov's 2024 knee cohort recorded a mean patient age of 31 — representative of the younger, active group in whom isolated focal cartilage damage tends to occur without concurrent generalised wear. Patients fitting that profile show the most consistent functional recovery across published series.

Joint location appears less decisive than defect character. Published evidence now extends across the knee, hip, ankle, and small joints of the wrist, with broadly comparable outcome patterns wherever the defect is focal and the surrounding joint is otherwise preserved. Where background disease is more advanced, results weaken regardless of which joint is involved.

Post-treatment activity restriction is a separate clinical consideration that affects planning rather than initial eligibility. The scaffold requires time to reach structural stability before normal joint loading resumes; the appropriate restriction period is determined at consultation based on defect size, location, and individual clinical factors.

What the evidence does not yet settle

The outcome figures discussed in earlier sections rest on a specific type of evidence: prospective cohort studies and post-market registries. Both are legitimate and informative — a prospective cohort follows real patients forward in time with pre-specified measurements, and a registry capturing over 19,000 cases carries genuine real-world weight. What neither provides is the controlled comparison that regulators and clinical guideline bodies require before one treatment can be ranked definitively against another.

That comparison was attempted. A 2016 randomised pilot pitted ChondroFiller against microfracture in a multicentre design, but the microfracture arm recorded a 60% dropout rate — leaving only four patients completing that pathway. With so few completing the control arm, no meaningful head-to-head analysis was possible, and the trial's comparative question remains unanswered.

The consequence is straightforward to state: ChondroFiller cannot yet be positioned definitively against established alternatives on the basis of comparative trial data alone. The 30-point IKDC gain, the 81% good-or-excellent durability rate at five years in hip patients, and the structural fill visible on MRI are all real findings — but whether those results are superior, equivalent, or inferior to microfracture or other scaffold approaches in a matched, powered study is not yet established.

For a patient or clinician, the practical frontier that a completed head-to-head trial would resolve is patient-level selection: specifically, whether younger active patients with defects in the 2–3 cm² range do meaningfully better with a collagen scaffold than with marrow-stimulation alone — a question the existing evidence base can encourage but not yet close.

1. [1] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Arthroscopic utilization of ChondroFiller gel for treatment of hip articular cartilage defects: cohort study with 12–60 month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z